Opioid use disorder

United States Transdermal Patch Market Report 2023: Dosage, Price & Clinical Trials Insights to 2029 - Focus on Opioid, Cardiovascular Diseases, Neurological Disorders, and Hormonal Therapy - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Medical Devices, Health, Gastritis, Brown University, Transdermal patch, Research, Indication, Chronic pain, Parkinson's disease, Pain management, Buprenorphine, University of California, Davis, Pregnancy, Patient, FDA, Alzheimer's disease, Opioid use disorder, Zydus Lifesciences, University, Cancer, Communication, Pain, Growth, Nerve, DSM-IV codes, Generic drug, Pharmaceutical industry, Adhesive, Birth control

The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • With the rapid approvals of transdermal patches lately, the FDA has also marked itself as an important player in the US market of transdermal patches.
  • The FDA provides a detailed communication on the requirements of an ideal transdermal patch, and patches that meet these are allowed entry in the regional market.
  • US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029 Report Highlights:
    US Transdermal Patch Market Opportunity: > US$ 5 Billion By 2029
    Commercially available Patches In US Market: > 25 Patches
    Ongoing Clinical Trials Of Transdermal Patches in US: > 40 Patches
    US Transdermal Patch Clinical Trials Insight By Company, Indication & Phase

SAMHSA Awards Eagle Technologies, Inc. CSAT Umbrella Evaluation Contract (CUEC) Program Evaluation

Retrieved on: 
Tuesday, November 21, 2023
Other Health, Software, Professional Services, Pharmaceutical, Data Management, Mental Health, White House, Federal Government, Technology, Health Technology, Data Analytics, Health, Public Policy, Government, Principal, Substance Abuse, Naloxone, Black, Treatment, Eagle, Project, SAMHSA, Opioid use disorder, Implementation, CSAT, Growth, Evaluation, Brandeis University, Lead, SOR, Life, Pharmaceutical industry, Research

The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded Eagle Technologies, Inc. (Eagle), and teaming partner, Brandeis University, a 5-year, $13 million contract to support SAMHSA’s Center for Substance Abuse Treatment (CSAT) beginning in September 2023.

Key Points: 
  • The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded Eagle Technologies, Inc. (Eagle), and teaming partner, Brandeis University, a 5-year, $13 million contract to support SAMHSA’s Center for Substance Abuse Treatment (CSAT) beginning in September 2023.
  • “The award is a big achievement for the growth of our Evaluation and Research business division,” remarked Eagle’s president Yilkal Abebe.
  • The Principal Investigator/Project Director is Linda Hermer, Ph.D., and the Project Manager/Analytics and Reporting Lead is Anand Borse, M.S., P.M.P.
  • Eagle goes above and beyond to deliver excellence and satisfaction—reflecting core values that define our company: effectiveness, innovation, dedication, and integrity.

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023
Post-traumatic stress disorder, FDA, Yale School of Medicine, Opioid use disorder, Standard of care, Intelligence, Government, Public Health Service Act, White House, Dexmedetomidine, Opioid epidemic, BID, Federal Food, Drug, and Cosmetic Act, Federation, Addiction, Xylazine, Psychiatry, COWS, Recreational drug use in Kenya, Locus coeruleus, Pharmacokinetics, OUD, National Institute on Drug Abuse, NIDA, Columbia University, NIH, Safety, Public, American Journal, Minneapolis Veterans Affairs Health Care System, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Fentanyl, Bangladesh Technical Education Board, RTI International, United States Public Health Service, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

Acadia Healthcare Reports Third Quarter 2023 Results and Updates Guidance Ranges to Reflect Continued Strong Business Growth and Momentum

Retrieved on: 
Thursday, November 2, 2023
Practice Management, Nursing, Managed Care, Health, Mental Health, Infectious Diseases, Hospitals, Other Health, Joint Ventures, PHP, Insurance, Opioid use disorder, Coronavirus, Intensive outpatient program, Economic security, IOP, Mental health, Form, Chinese, PRF, Economy of Salt Lake City, Growth, ECU Health, Salt Lake City, Hospital, Hand, Overalls, Investment, Economy, Patient, Bed, Pharmaceutical industry

Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2023.
  • Chris Hunter, Chief Executive Officer of Acadia, remarked, “Our results for the third quarter reflect our continued execution on our growth strategy as well as strong operational execution across all four of our business lines.
  • “We produced strong financial results with impressive top line growth and favorable volume trends compared with the third quarter of 2022.
  • We expect the strategic technology investments we have made will further enhance our performance, drive efficiencies, and support strong clinical outcomes.

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

Retrieved on: 
Wednesday, November 1, 2023
A Jolly Good Fellow (novel), Post-traumatic stress disorder, Anxiety, VR, Cognitive behavioral therapy, Johns Hopkins University, University of Oxford, Chronic pain, United States Department of Veterans Affairs, Boston University Chobanian & Avedisian School of Medicine, SCI, Veterans' affairs, QOL, Veteran, University of Bath Department of Psychology, Opioid use disorder, Research, Chūō-ku, State, Death, PTSD, Quality of life, Learning, Feel Good Inc., Psychology, Boston University School of Public Health, Teaching, Boston University, Apple, Pain, DSM-IV codes, Eye, Opioid, CBT, Cancer, Pain management, Behavioral medicine, Patient, Doctor of Philosophy, Poultry farming, Video game, Nursing, Pharmaceutical industry, Dentistry, Neuroscience

TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.

Key Points: 
  • Chronic Pain Experts
    TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.
  • In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.
  • Opioid abuse and addiction are currently a major social problem in the United States, and many people who take them experience chronic pain.
  • Through this experience, we aim to provide medical education and mental illness treatment using live-action 360-degree video, which is a feature of Jolly Good.

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
General Health, Pharmaceutical, Health, FDA, United Kingdom, Naltrexone, Epidemiology, Naloxone, Expert Opinion on Emerging Drugs, Therapy, Medicare, Organ donation after medical assistance in dying, Opioid use disorder, VIVITROL, Community Living Assistance Services and Supports Act, OTP, Disease, Methadone, OUD, Growth, Medicaid, COVID-19, Drug, EU4, Vaccine, Cereal, Pharmaceutical industry, Medical device, Dentistry, Health insurance, Health care, Buprenorphine, Indivior

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Retrieved on: 
Thursday, October 19, 2023
OUD, Opioid use disorder, AUD, Patent, Patient, Pharmaceutical industry

“This patent marks another important milestone in our pursuit to provide tailored, more effective treatments for individuals grappling with AUD and OUD,” stated Cary Claiborne, CEO of Adial Pharmaceuticals.

Key Points: 
  • “This patent marks another important milestone in our pursuit to provide tailored, more effective treatments for individuals grappling with AUD and OUD,” stated Cary Claiborne, CEO of Adial Pharmaceuticals.
  • “By combining our novel genetic diagnostic with AD04, a potentially transformative therapy for those battling AUD and OUD, we aim to optimize therapeutic outcomes, ensuring that patients receive the most suitable treatment for their unique genetic profile.”
    The recently awarded patent further enhances Adial Pharmaceuticals' position at the forefront of personalized medicine in addiction therapy.
  • Recognizing that every patient’s genetic makeup is different, the proprietary diagnostic tool is designed to predict which patients are most likely to benefit from AD04 treatment.
  • “This patent is a further testament to our commitment to harnessing cutting-edge science for the betterment of countless lives affected by addiction.

Study Reveals the Need to Expand Maternal Mortality Categorization Beyond Pregnancy-Related Deaths

Retrieved on: 
Wednesday, October 25, 2023
Research, Opioid use disorder, Comorbidity, Maternal health, Department of Obstetrics and Gynecology (Massachusetts General Hospital), SMM, MPH, Black Maternal Health Caucus, Disease, Massachusetts Department of Public Health, Public health, Mortality, Obstetrics and gynaecology, University of California, Boston University School of Public Health, Tufts University School of Medicine, Death, Reproductive Sciences, Hospital, Risk, Pregnancy, University, NIH, Public, ER, Dietary supplement, Birth control, Gynaecology, Doctor of Philosophy, Obstetrics

BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large. Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019. It also identified four times as many pregnancy-associated deaths than pregnancy-related ones and a high rate of hospital contacts (hospital admission, observational stays, and ER visits) for those who ultimately died during pregnancy through one year postpartum.

Key Points: 
  • New Research Shows Prior Hospitalization, Severe Maternal Morbidity, and Opioid Use Disorder Were Key Contributors to Pregnancy-Associated Deaths in Massachusetts from 2002 to 2019.
  • BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large.
  • Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019.
  • There is a clear need to expand the focus of maternal mortality to the much larger group of pregnancy-associated deaths to understand the risk factors and events that lead to many of these preventable deaths."

CARI Health Awarded NIH Grant of up to $2.8M to Advance Remote Medication Monitoring

Retrieved on: 
Thursday, October 19, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Health Technology, Biometrics, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Digital, Research, Opioid use disorder, Marianne Schmidl, SDAC, Global Entrepreneur, UCSD, Medtech, Conference, Methadone, CARI, National Institute on Drug Abuse, NIDA, University, Device, NIH, Investment, Patient, Bangladesh Technical Education Board, Pharmaceutical industry

Digital health startup CARI Health was awarded an SBIR Fast Track grant from the National Institute on Drug Abuse (NIDA), an agency of the National Institutes of Health (NIH), to help it bring the world’s first wearable medication monitor to market.

Key Points: 
  • Digital health startup CARI Health was awarded an SBIR Fast Track grant from the National Institute on Drug Abuse (NIDA), an agency of the National Institutes of Health (NIH), to help it bring the world’s first wearable medication monitor to market.
  • CARI Health is eligible for up to $2.8M over three years as project milestones are successfully completed within Phase I and Phase II portions of the grant.
  • The award funding will go toward supporting product development and conducting human clinical studies for CARI Health’s wearable remote medication monitoring device .
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Mass General Brigham, Buprenorphine, Opioid use disorder, Harvard Medical School, IND, Drug, McLean Hospital, Assistant, U.S. government and smoking cessation, Psychiatry, Doctor of Philosophy, Naltrexone, Methadone, Development, OUD, National Institute on Drug Abuse, NIDA, Immunoglobulin G, Research and development, Blood, Brain, Mass, Therapy, Fentanyl, Bangladesh Technical Education Board, Pharmaceutical industry

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.